Claims for Patent: 7,041,312

Summary for Patent: 7,041,312

Title:	Wound healing compositions and methods of use
Abstract:	A wound-healing composition comprises a wound-treating component and vesicles. The vesicles comprise a phospholipid which is a stable vesicle former and ATP.
Inventor(s):	Ehringer; William D. (Charlestown, IN), Chien; Sufan (Floyd Knobbs, IN)
Assignee:	University of Louisville Research Foundation, Inc. (Louisville, KY)
Application Number:	10/627,195
Patent Claims:	1. A wound-healing composition, comprising: a wound-treating component; and fusogenic vesicles, wherein the vesicles comprise: a phospholipid which is a stable vesicle former, wherein the phospholipid is a phosphatidylcholine; at least one unstable vesicle forming member, wherein the unstable vesicle forming member is PEG or polar lipid having the structure of formula (I) X-L-Z.sub.2 (I) wherein X is H or a head group comprising a polar group selected from the group consisting of formulas (III), (IV), (V), (VI), and (VII) ##STR00004## L is an alkyl further missing two hydrogen atoms, and each Z is independently H, E, or the structure of formula (XI), ##STR00005## wherein E is an alkyl or alkenyl, and when one Z is H, the other Z is not H; and ATP at a concentration of 1 mM to 50 mM, wherein the vesicles have a ratio of the stable vesicle former to the unstable vesicle forming member of 1:1 to 500:1 and a fusion rate of at least 20 vesicle fusions/second. 2. The wound-healing composition of claim 1, wherein the wound-treating component comprises at least one member selected from the group consisting of an antiseptic, an antibiotic, and an anesthetic. 3. The wound-healing composition of claim 1, wherein the wound-treating component comprises becaplermin. 4. The wound-healing composition of claim 1, wherein the at least one unstable vesicle forming member is PEG. 5. A method for promoting wound healing, comprising contacting a wound with the wound-healing composition of claim 1. 6. The method of claim 5, wherein the wound is a superficial wound. 7. The wound-healing composition of claim 1, wherein the at least one unstable vesicle forming member is the polar lipid. 8. The wound-healing composition of claim 1, wherein the fusion rate is at least 10.sup.3 vesicle fusions/second. 9. The wound-healing composition of claim 1, wherein the fusion rate is at least 10.sup.6 vesicle fusions/second. 10. A wound-healing composition, comprising: at least one member selected from the group consisting of an antiseptic, an antibiotic, and an anesthetic; and fusogenic vesicles comprising: ATP at a concentration of 1 mM to 50 mM, DOPC, and POPA, wherein a ratio of DOPC:POPA is 1:1 to 500:1. 11. The wound-healing composition of claim 10, wherein a ratio of DOPC:POPA is 10:1 to 100:1. 12. A wound-healing composition, comprising: becaplermin; and fusogenic vesicles comprising: ATP at a concentration of 1 mM to 50 mM, DOPC, and POPA, wherein a ratio of DOPC:POPA is 1:1 to 500:1.

Details for Patent 7,041,312

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	12/16/1997		2022-05-14